BLS Pharmaceuticals Ltd - Company Profile
Powered by 
All the sales intelligence you need on BLS Pharmaceuticals Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how BLS Pharmaceuticals Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with BLS Pharmaceuticals Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BLS Pharmaceuticals Ltd (BLS) is a life sciences company. It manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative novel medicines. BLS focuses on the pharmaceutical manufacturing and wholesale supply of novel medicines, medicinal cannabis, psilocybin, and 4-Methylenedioxymethamphetamine (MDMA) through BLS Wholesalers Pty Limited; the manufacture and distribution of consumer health products, including cannabidiol and functional mushrooms under the Dr Watson brand across the UK, Europe, and Japan; and the wholesale distribution of patented probiotics for gastrointestinal health and immunity, primarily to the US. The company has manufacturing and distribution centers in Australia, Japan, the UK, and Europe. BLS is headquartered in Sydney, New South Wales, Australia.
Headquarters
Australia
Address
Suite 506, Level 5, 50 Clarence Street, Sydney, New South Wales, 2000
Website
www.bioxyne.com
Telephone
61 2 90788180
No of Employees
16
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BXN (ASX)
Revenue (2024)
$19.3M
203.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
136.8%
(2024 vs 2023)
Market Cap*
$125.2M
Net Profit Margin (2024)
XYZ
112.1%
(2024 vs 2023)
* As of and is in US$
BLS Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Novel Medicines | Dr Watson |
| Medicinal Cannabis | Breathe Life Sciences |
| Psilocybin | BLS Clinics |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In December, the company's subsidiary, Breathe Life Sciences (BLS), entered into a manufacturing and supply agreement with Remidose LATAM SRL, to facilitate Bioxyne's entry into the medicinal cannabis markets of Costa Rica and Panama. |
| 2024 | New Products/Services | In August, the company manufactured and delivered Australia’s first pharmaceutical cannabis pastilles (Gummies or Edibles). |
| 2024 | Contracts/Agreements | In May, the company entered into a commercial supply and collaboration agreement with Cy Biopharma AG of Switzerland. |
Competitor Comparison
| Key Parameters | BLS Pharmaceuticals Ltd | Probiotec Ltd | BLIS Technologies Ltd | Amplia Therapeutics Ltd | BioCeuticals Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | New Zealand | Australia | Australia |
| City | Sydney | Melbourne | Dunedin | Melbourne | Surry Hills |
| State/Province | New South Wales | Victoria | Otago | Victoria | New South Wales |
| No. of Employees | 16 | 111 | 38 | 1 | - |
| Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Samuel Watson | Chief Executive Officer; Managing Director | Executive Board | 2023 | - |
| Jason Hine | Chief Operating Officer; Director | Executive Board | 2023 | - |
| Guy Robertson | Chief Financial Officer; Secretary | Senior Management | 2016 | - |
| Anthony Ho | Chairman | Non Executive Board | 2012 | - |
| Jason Stephens | General Manager - BLS Australia | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer